Soria JC - Search Results

1

Evaluation of the VeriStrat^® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A. Gadgeel S, et al. Among authors: soria jc. Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11. Lung Cancer. 2017. PMID: 28577938 Free article. Clinical Trial.

2

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

Soria JC, Brisgand D, Le Chevalier T. Soria JC, et al. Ann Oncol. 2001 Dec;12(12):1667-70. doi: 10.1023/a:1013574413217. Ann Oncol. 2001. PMID: 11843242 Free article. Clinical Trial.

3

Imatinib in small cell lung cancer.

Soria JC, Johnson BE, Chevalier TL. Soria JC, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S49-53. doi: 10.1016/s0169-5002(03)00142-9. Lung Cancer. 2003. PMID: 12867062 Clinical Trial.

4

Uncertain benefit from surgery in patients with lung metastases from breast carcinoma.

Planchard D, Soria JC, Michiels S, Grunenwald D, Validire P, Caliandro R, Girard P, Le Chevalier T. Planchard D, et al. Among authors: soria jc. Cancer. 2004 Jan 1;100(1):28-35. doi: 10.1002/cncr.11881. Cancer. 2004. PMID: 14692021 Free article.

5

[Adjuvant chemotherapy in non-small cell lung cancer].

Taillade L, Soria JC, André F, Grunenwald D, Dunant A, Pignon JP, Le Chevalier T. Taillade L, et al. Among authors: soria jc. Bull Cancer. 2004 Jan;91(1):63-7. Bull Cancer. 2004. PMID: 14975806 Free article. Review. French.

6

Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.

Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Delbaldo C, et al. Among authors: soria jc. JAMA. 2004 Jul 28;292(4):470-84. doi: 10.1001/jama.292.4.470. JAMA. 2004. PMID: 15280345

7

Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features.

Erman M, Grunenwald D, Penault-Llorca F, Grenier J, Besse B, Validire P, Morat L, Girard P, Le Chevalier T, Sabatier L, Soria JC. Erman M, et al. Among authors: soria jc. Lung Cancer. 2005 Mar;47(3):315-23. doi: 10.1016/j.lungcan.2004.08.015. Lung Cancer. 2005. PMID: 15713515

8

Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.

Achille M, Gallegos-Ruiz M, Giaccone G, Soria JC. Achille M, et al. Among authors: soria jc. Clin Lung Cancer. 2006 Nov;8(3):214-6. doi: 10.3816/CLC.2006.n.050. Clin Lung Cancer. 2006. PMID: 17239298

9

Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.

Wagner M, Besse B, Balleyguier C, Soria JC. Wagner M, et al. Among authors: soria jc. J Thorac Oncol. 2008 Jun;3(6):677-9. doi: 10.1097/JTO.0b013e3181757a8b. J Thorac Oncol. 2008. PMID: 18520813 Free article. No abstract available.

10

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F. Soria JC, et al. J Clin Oncol. 2011 Nov 20;29(33):4442-51. doi: 10.1200/JCO.2011.37.2623. Epub 2011 Oct 17. J Clin Oncol. 2011. PMID: 22010015 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

732 results

Search Page